Daily Stock Opinions and Ratings

Opinions

Cameron Hurst Spdr S&P Biotech Etf XBI-N TOP PICK Oct 10, 2017

This is equal weighted, so you are getting a split between the big hefty diversifieds. M&A, which has been highlighted by Gilead, is definitely driving the sector now. At the same time, you are getting the basket approach of the big guys, you are incorporating the small guys as take-out targets that give you the big premium. There is a slightly softer regulatory environment where more drugs are making it to market.

Cameron Hurst

Owned

Unlock Rating

$87.630

Stock price when the opinion was issued

E.T.F.'s

It's the ideal tool to help you make quicker, more informed decisions for managing and tracking your investments.

Get Signals Create your Watchlist

You might be interested:

BUY

The sector has had a great bounce since March lows. A good way to play the COVID vaccine race. IBB is the best-known biotech ETF, but he does the XBI, because it's equal-weighted. XBI has had a great bounce. It's a great sector with reasonable valuations. The race for a COVID vaccine is a tailwind, of course. Biotech is a slow-growth area, which benefit from interest rates staying very low for the long term.

SELL ON STRENGTH

Exposure to the covid vaccine is quite minimal in this ETF. Very short term over-bought and he expects a 10-15% correction. Trim some exposure into strength. Longer term, the biotech sector looks good.

BUY

options He normally won't buy an ETF, but someone bought 20,000 of the May 95 strike calls for a little over $1.00. It's a very diverse diverse biotech ETF.

WEAK BUY

Many biotech companies are trading below their cash levels. He doesn't own the stocks, but is good with ETFs like this. He expects more M&A in biotechs as big pharma buys these companies.

BUY

Owning a biotech ETF like XBI is fine for risk management. Healthcare is recession-resistant and he loves it.

BUY

She's very bullish healthcare. Buy it at $83. She's selling the $90 September calls, collecting $3.25.

BUY

XBI has been in the $80-90 range. Has strong free cash flow. A good way to diversify away from tech. You can sell calls against it.

SELL

Bought it last year, and just sold it. This stock has broken down.

BUY

Healthcare has been an ignored sector, but is enjoying some momentum and will do well in second-half 2024. McKesson, Merck and Amgen, all holdings in this ETF, are doing well and even making new highs. Also, biotech does well when rates come down.

DON'T BUY

Biotechs look speculative in profitability. She prefers big pharma, seeing continued value, despite big moves in stocks.

Stockchase, in its reporting on what has been discussed by individuals on business television programs (in particular Business News Network), neither recommends nor promotes any investment strategies.

We paraphrase the experts by hand, we watch the shows and write down what we understood from the experts’ comments. We are human and can make mistakes, help us fix any errors. If you see something that you know is not right or if there is a problem with the site, feel free to email us at : hello@stockchase.com.

Cameron Hurst Spdr S&P Biotech Etf XBI-N TOP PICK Oct 10, 2017

You might be interested:

Spdr S&P Biotech Etf(XBI-N)

Spdr S&P Biotech Etf(XBI-N)

Spdr S&P Biotech Etf(XBI-N)

Spdr S&P Biotech Etf(XBI-N)

Spdr S&P Biotech Etf(XBI-N)

Spdr S&P Biotech Etf(XBI-N)

Spdr S&P Biotech Etf(XBI-N)

Spdr S&P Biotech Etf(XBI-N)

Spdr S&P Biotech Etf(XBI-N)

Spdr S&P Biotech Etf(XBI-N)

Latest Buy Signals

Today's Top Picks

Popular Articles

Latest Sell Signals

Most Recent Experts

Bruce Murray

The Panic-Proof Portfolio (Stockchase Research)

The Weekly Buzzing Stocks by Billy Kawasaki

Chris Blumas

Stockchase Insights